Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ueda, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ueda, R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology Pages 1-2

Editorial
Editorial

How can we predict and prevent the occurrence of therapy-related Leukemias ?

Ryuzo Ueda, Second Department of Internal Medicine, Nagoya City University Medical School, Nagoya, Japan

Advances in the fields of chemotherapy and radiotherapy have improved the survival period of cancer patients over the last few decades. Unfortunately, an unpredicted disaster has also resulted from this medical progress, the `therapy-related leukemia (TRL)' which is increasingly a focus of attention for oncologists (1). It was initially described by hematologists, particularly among long-term survivors from Hodgkin's disease, whose treatment regimens included alkylating agents and combined-modality therapy using chemotherapy and radiotherapy. Based on accumulated experience, treatment regimens for Hodgkin's disease have been changed with the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?